Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial☆
To access this article, please choose from the options below
☆ Financial support: The APEX-AMI trial, from which this work was derived, was supported by a research grant jointly funded from Procter & Gamble and Alexion Pharmaceuticals.
PII: S0022-0736(10)00185-8
doi:10.1016/j.jelectrocard.2010.04.001
© 2010 Elsevier Inc. All rights reserved.
